CASZ1 is a novel promoter of metastasis in ovarian cancer

Yi Ying Wu, Chia Lin Chang, Yuan Jhe Chuang, Jia En Wu, Chia Hao Tung, Yeong Chang Chen, Yuh-Ling Chen, Tse-Ming Hong, Keng-Fu Hsu

研究成果: Article

1 引文 (Scopus)

摘要

Epithelial ovarian cancer (EOC) carries the highest mortality rate of all gynecologic malignancies. This high mortality rate is attributed to the fact that most cases of ovarian cancer are detected at late stages when metastases are already present. Through microarray analysis, we previously demonstrated that castor zinc finger 1 (CASZ1) is up-regulated in EOC cells. In contrast to its role in EOC, CASZ1 functions a tumor suppressor in neuroblastoma. Human CASZ1 is predominantly expressed in 2 alternatively spliced isoforms: CASZ1a and CASZ1b. In the present study, we investigated the role of CASZ1 in ovarian cancer cell migration and invasion and assessed the value of CASZ1 expression as a prognostic indicator of metastasis in human ovarian cancer. We used a lentivirus expressing CASZ1-shRNA and a plasmid expressing CASZ1 from a CMV promoter to knockdown and overexpress CASZ1, respectively, in the MCAS, RMUG-S, TOV21G, and A2780CP70 ovarian cancer cell lines. mRNA expression levels in tumor tissues and cell lines were measured using quantitative real-time PCR, and CASZ1 protein expression in EOC and paired metastatic tumor tissues was analyzed using immunohistochemistry. We found that CASZ1 was highly expressed in EOC tissues and ovarian cancer cell lines and that CASZ1 knockdown suppressed cell migration and invasion in EOC cells. CASZ1a and CASZ1b exerted similar effects on cell migration and invasion in EOC cells. In addition, CASZ1 promoted the epithelial-mesenchymal transition in EOC cells, and CASZ1 knockdown suppressed cancer metastasis in vivo. Furthermore, CASZ1 protein levels were elevated in human metastatic ovarian tumor tissues. Together, these results indicate that CASZ1 is a novel promoter of EOC metastasis and is highly up-regulated in metastatic EOC tumors.

原文English
頁(從 - 到)1253-1270
頁數18
期刊American Journal of Cancer Research
6
發行號6
出版狀態Published - 2016 一月 1

指紋

Zinc Fingers
Ovarian Neoplasms
Neoplasm Metastasis
Cell Movement
Neoplasms
Ovarian epithelial cancer
Cell Line
Lentivirus
Epithelial-Mesenchymal Transition
Mortality
Microarray Analysis
Tumor Cell Line
Neuroblastoma
Small Interfering RNA
Real-Time Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

引用此文

Wu, Y. Y., Chang, C. L., Chuang, Y. J., Wu, J. E., Tung, C. H., Chen, Y. C., ... Hsu, K-F. (2016). CASZ1 is a novel promoter of metastasis in ovarian cancer. American Journal of Cancer Research, 6(6), 1253-1270.
Wu, Yi Ying ; Chang, Chia Lin ; Chuang, Yuan Jhe ; Wu, Jia En ; Tung, Chia Hao ; Chen, Yeong Chang ; Chen, Yuh-Ling ; Hong, Tse-Ming ; Hsu, Keng-Fu. / CASZ1 is a novel promoter of metastasis in ovarian cancer. 於: American Journal of Cancer Research. 2016 ; 卷 6, 編號 6. 頁 1253-1270.
@article{e7cf0bb3d5254650b1000cef66b46a5b,
title = "CASZ1 is a novel promoter of metastasis in ovarian cancer",
abstract = "Epithelial ovarian cancer (EOC) carries the highest mortality rate of all gynecologic malignancies. This high mortality rate is attributed to the fact that most cases of ovarian cancer are detected at late stages when metastases are already present. Through microarray analysis, we previously demonstrated that castor zinc finger 1 (CASZ1) is up-regulated in EOC cells. In contrast to its role in EOC, CASZ1 functions a tumor suppressor in neuroblastoma. Human CASZ1 is predominantly expressed in 2 alternatively spliced isoforms: CASZ1a and CASZ1b. In the present study, we investigated the role of CASZ1 in ovarian cancer cell migration and invasion and assessed the value of CASZ1 expression as a prognostic indicator of metastasis in human ovarian cancer. We used a lentivirus expressing CASZ1-shRNA and a plasmid expressing CASZ1 from a CMV promoter to knockdown and overexpress CASZ1, respectively, in the MCAS, RMUG-S, TOV21G, and A2780CP70 ovarian cancer cell lines. mRNA expression levels in tumor tissues and cell lines were measured using quantitative real-time PCR, and CASZ1 protein expression in EOC and paired metastatic tumor tissues was analyzed using immunohistochemistry. We found that CASZ1 was highly expressed in EOC tissues and ovarian cancer cell lines and that CASZ1 knockdown suppressed cell migration and invasion in EOC cells. CASZ1a and CASZ1b exerted similar effects on cell migration and invasion in EOC cells. In addition, CASZ1 promoted the epithelial-mesenchymal transition in EOC cells, and CASZ1 knockdown suppressed cancer metastasis in vivo. Furthermore, CASZ1 protein levels were elevated in human metastatic ovarian tumor tissues. Together, these results indicate that CASZ1 is a novel promoter of EOC metastasis and is highly up-regulated in metastatic EOC tumors.",
author = "Wu, {Yi Ying} and Chang, {Chia Lin} and Chuang, {Yuan Jhe} and Wu, {Jia En} and Tung, {Chia Hao} and Chen, {Yeong Chang} and Yuh-Ling Chen and Tse-Ming Hong and Keng-Fu Hsu",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "1253--1270",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "6",

}

Wu, YY, Chang, CL, Chuang, YJ, Wu, JE, Tung, CH, Chen, YC, Chen, Y-L, Hong, T-M & Hsu, K-F 2016, 'CASZ1 is a novel promoter of metastasis in ovarian cancer', American Journal of Cancer Research, 卷 6, 編號 6, 頁 1253-1270.

CASZ1 is a novel promoter of metastasis in ovarian cancer. / Wu, Yi Ying; Chang, Chia Lin; Chuang, Yuan Jhe; Wu, Jia En; Tung, Chia Hao; Chen, Yeong Chang; Chen, Yuh-Ling; Hong, Tse-Ming; Hsu, Keng-Fu.

於: American Journal of Cancer Research, 卷 6, 編號 6, 01.01.2016, p. 1253-1270.

研究成果: Article

TY - JOUR

T1 - CASZ1 is a novel promoter of metastasis in ovarian cancer

AU - Wu, Yi Ying

AU - Chang, Chia Lin

AU - Chuang, Yuan Jhe

AU - Wu, Jia En

AU - Tung, Chia Hao

AU - Chen, Yeong Chang

AU - Chen, Yuh-Ling

AU - Hong, Tse-Ming

AU - Hsu, Keng-Fu

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Epithelial ovarian cancer (EOC) carries the highest mortality rate of all gynecologic malignancies. This high mortality rate is attributed to the fact that most cases of ovarian cancer are detected at late stages when metastases are already present. Through microarray analysis, we previously demonstrated that castor zinc finger 1 (CASZ1) is up-regulated in EOC cells. In contrast to its role in EOC, CASZ1 functions a tumor suppressor in neuroblastoma. Human CASZ1 is predominantly expressed in 2 alternatively spliced isoforms: CASZ1a and CASZ1b. In the present study, we investigated the role of CASZ1 in ovarian cancer cell migration and invasion and assessed the value of CASZ1 expression as a prognostic indicator of metastasis in human ovarian cancer. We used a lentivirus expressing CASZ1-shRNA and a plasmid expressing CASZ1 from a CMV promoter to knockdown and overexpress CASZ1, respectively, in the MCAS, RMUG-S, TOV21G, and A2780CP70 ovarian cancer cell lines. mRNA expression levels in tumor tissues and cell lines were measured using quantitative real-time PCR, and CASZ1 protein expression in EOC and paired metastatic tumor tissues was analyzed using immunohistochemistry. We found that CASZ1 was highly expressed in EOC tissues and ovarian cancer cell lines and that CASZ1 knockdown suppressed cell migration and invasion in EOC cells. CASZ1a and CASZ1b exerted similar effects on cell migration and invasion in EOC cells. In addition, CASZ1 promoted the epithelial-mesenchymal transition in EOC cells, and CASZ1 knockdown suppressed cancer metastasis in vivo. Furthermore, CASZ1 protein levels were elevated in human metastatic ovarian tumor tissues. Together, these results indicate that CASZ1 is a novel promoter of EOC metastasis and is highly up-regulated in metastatic EOC tumors.

AB - Epithelial ovarian cancer (EOC) carries the highest mortality rate of all gynecologic malignancies. This high mortality rate is attributed to the fact that most cases of ovarian cancer are detected at late stages when metastases are already present. Through microarray analysis, we previously demonstrated that castor zinc finger 1 (CASZ1) is up-regulated in EOC cells. In contrast to its role in EOC, CASZ1 functions a tumor suppressor in neuroblastoma. Human CASZ1 is predominantly expressed in 2 alternatively spliced isoforms: CASZ1a and CASZ1b. In the present study, we investigated the role of CASZ1 in ovarian cancer cell migration and invasion and assessed the value of CASZ1 expression as a prognostic indicator of metastasis in human ovarian cancer. We used a lentivirus expressing CASZ1-shRNA and a plasmid expressing CASZ1 from a CMV promoter to knockdown and overexpress CASZ1, respectively, in the MCAS, RMUG-S, TOV21G, and A2780CP70 ovarian cancer cell lines. mRNA expression levels in tumor tissues and cell lines were measured using quantitative real-time PCR, and CASZ1 protein expression in EOC and paired metastatic tumor tissues was analyzed using immunohistochemistry. We found that CASZ1 was highly expressed in EOC tissues and ovarian cancer cell lines and that CASZ1 knockdown suppressed cell migration and invasion in EOC cells. CASZ1a and CASZ1b exerted similar effects on cell migration and invasion in EOC cells. In addition, CASZ1 promoted the epithelial-mesenchymal transition in EOC cells, and CASZ1 knockdown suppressed cancer metastasis in vivo. Furthermore, CASZ1 protein levels were elevated in human metastatic ovarian tumor tissues. Together, these results indicate that CASZ1 is a novel promoter of EOC metastasis and is highly up-regulated in metastatic EOC tumors.

UR - http://www.scopus.com/inward/record.url?scp=84991525028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991525028&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84991525028

VL - 6

SP - 1253

EP - 1270

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 6

ER -

Wu YY, Chang CL, Chuang YJ, Wu JE, Tung CH, Chen YC 等. CASZ1 is a novel promoter of metastasis in ovarian cancer. American Journal of Cancer Research. 2016 1月 1;6(6):1253-1270.